A genomic expression library of Leishmania aethiopica was constructed in Xgtll and screened with patient sera and sera from healthy people living in an area of endemicity. Forty-five recombinant clones were isolated and partly characterized. Clone-specific antibodies were prepared and used with sodium dodecyl sulfatepolyacrylamide gel electrophoresis and Western immunoblot analysis to estimate the molecular masses of the parasite-derived antigens containing the reactive epitope(s). Antigens with apparent molecular masses of 90, 85, 63, 50, 41, 25 and 24 kDa as well as several antigens with lower molecular masses were detected. The clone-specific antibodies from patients with diffuse cutaneous leishmaniasis reacted with high-molecular-weight antigens (30,000 < Mr < 90,000), whereas antibodies from patients with localized cutaneous leishmaniasis recognized low-molecular-weight antigens (Mr < 25,000). Nine different purified recombinant antigens were obtained from lysogens in Escherichia coli Y1089 by immunoaffinity chromatography on anti-f-galactosidase columns and were subsequently tested with patient sera. It is suggested that some of these recombinant antigens might be used for immunodiagnostic purposes.
Leishmania aethiopica is the causative agent of the two forms of leishmaniasis found in the highlands of Ethiopia (2, 13) , diffuse cutaneous leishmaniasis (DCL) and localized cutaneous leishmaniasis (LCL). The first form shows multiple skin lesions on the face, trunk, and extremities and is usually not self-healing, whereas LCL is mostly seen as single lesions which are self-healing over time. Previous studies have shown that DCL patients have reduced lymphocyte proliferation in vitro to specific leishmania antigens (4, 11) , in contrast to LCL patients. Also, the humoral responses in DCL patients are manifested by the presence of antibodies with specificities against antigens of different size, whereas antibodies in sera from LCL patients showed a limited recognition of the low-molecular-weight antigens (12) . Whether the two forms of the disease are caused by the same strain(s) of L. aethiopica is not clear. Both differences in the immune response of the infected patient (3) and differences of the infecting parasites (1) have been proposed as an explanation for the difference in clinical manifestations between DCL and LCL.
The study of L. aethiopica antigens, especially from the intracellular amastigote form, has been limited because of a lack of pure antigens. In order to overcome these problems, a genomic expression library has been constructed in order to isolate and characterize recombinant Xgtll clones expressing antigenic determinants that may play a role in the pathogenesis of the disease. Such recombinant antigens may become important both as diagnostic tools and for future vaccine purposes.
In this paper we report on the screening of the library and on the purification and characterization of recombinant antigens that react with patient sera and sera from healthy people living in areas where leishmaniasis is endemic.
MATERIALS AND METHODS
Parasites and serum samples. L. aethiopica isolates 080 (DCL) and 1467 (LCL), originally isolated from patients at the ALERT hospital, Addis Ababa, Ethiopia, and isolates GG (DCL) and K499 (LCL), originally isolated from the district of Ocholo in Ethiopia, were all from the Armauer Hansen Research Institute collection.
Promastigotes were grown in RPMI 1640 supplemented with 10% heat-inactivated fetal calf serum, 100 U of penicillin per ml, 100 ,g of streptomycin per ml, and 2 mM L-glutamine at 25°C. The Preparation of clone-specific antibodies. The preparation of clone-specific antibodies followed mainly a protocol described earlier (14) . From Analysis of parasite lysate. Parasites (2 x 109) were washed twice with phosphate-buffered saline (PBS) and resuspended in 8 ml of PBS containing 10 mM EDTA and 2 mM phenylmethylsulfonyl fluoride. The suspension was sonicated and immediately frozen in aliquots at -70°C. Protein concentration was measured by using a protein assay kit (Bio-Rad) and bovine serum albumin as a standard. Proteins of the parasite lysate were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (7) and transferred to nitrocellulose filters by Western immunoblotting (0.2 A for 2 h) (18) with 0.5 mg of protein per cm of gel applied. After being blotted, the nitrocellulose filters were blocked with OA-TBS-azide overnight and cut into 4-mm strips. Each strip was then incubated with a clonespecific antibody preparation for 20 h, washed four times (15 min each) with TBS-azide, and incubated with secondary antibody followed by substrate solution as described for the screening procedure. The apparent molecular masses of the parasite antigens were estimated by comparison with the migration of prestained markers (Sigma Chemical Co., St. Louis, Mo.) run on the same gel.
Analysis of DNA insert. The DNA inserts were amplified by using the polymerase chain reaction (PCR) (15) . Phage (106 to 107) from isolated plaques or from high-titer lysates of each clone was added to 100 ,ul of PCR buffer containing 1 mM deoxynucleotides, 100 ,uM Xgtll forward and reverse primers (Promega) and Taq polymerase (4 U) (Promega). Next, 30 cycles were performed by using the following temperature profile: 30 s at 95°C, 30 s at 55°C, and 2 min at 63°C. The amplified inserts were then analyzed by agarose gel electrophoresis with HaeIII-digested 4X174 DNA (Pharmacia, Uppsala, Sweden) as molecular weight markers.
DNA sequencing of inserts was performed by using the PCR-amplified inserts as templates and 32P-end-labelled primer (10) . Primers (24-mers, forward and reverse) were phosphorylated with polynucleotide kinase and [-y-32P]ATP (>5,000 Ci/mmol) (Amersham International, Amersham, United Kingdom). DNA sequencing was performed by using a protocol and kit (Promega) for sequencing with A as a template.
Preparation and purification of recombinant antigens. Lysogens of the different clones were made in E. coli Y1089. Cultures (100 ml) were grown and induced, and ammonium sulfate precipitates of the recombinant antigens were prepared as previously described (6) . The recombinant antigens were further purified by immunoaffinity chromatography with 1 ml of anti-i-galactosidase columns (Promega) as described by the manufacturer. The recombinant antigens were eluted with 2 ml of 100 mM sodium bicarbonatecarbonate buffer, pH 10.8, the eluates were immediately neutralized by adding 200 ,ul of 1 M Tris-HCl, pH 7.4, and the preparations were frozen at -70°C.
Analysis of recombinant antigen. Ammonium sulfate precipitates of recombinant antigens were tested by SDS-PAGE and Western blot analysis, which was followed by probing with anti-,B-galactosidase mouse monoclonal antibody diluted 1:500 in OA-TBS-azide and with goat anti-mouse IgG conjugated with alkaline phosphatase diluted 1:5,000 in OA-TBS-azide (both from Promega). These preparations were also tested in dot blots on NC filters and probed with human sera depleted of anti-E. coli antibodies and goat anti-human IgG conjugated with alkaline phosphatase as described for the screening procedure.
The purified recombinant antigens were analyzed by SDS-PAGE and then by Coomassie staining to assess the purity of the preparations. In results showed that of 41 clone-specific antibodies tested, 28 reacted positively and gave one or more bands in the Western blots ( Fig. 1 and Table 1 ). The antigens detected in the two different lysates (DCL and LCL) by the different clone-specific antibodies were identical. Only minor differences, e.g., intensity of bands, could be observed.
The apparent molecular masses of the antigens detected were found to be equal to or less than 90 kDa. The clonespecific antibodies from the DCL sera (sera 885 and 886) identified antigens with apparent molecular masses of 90, 85, 63, 50, and 41 kDa ( These preparations of recombinant antigens were also tested in dot blots and probed with patient sera. The results showed that most of the antigens seem to contain intact antigenic determinants (Fig. 2) . Further purification of these antigens was performed by using immunoaffinity chromatography, and the antigen preparations were then analyzed by SDS-PAGE and then by Coomassie staining. Of the 31 antigenic preparations tested by SDS-PAGE, 9 showed clear bands in the gel indicating molecular weights equal to or higher than that of 3-galactosidase (Fig. 3) . These 9 recombinant proteins represent 30% of the lysogens that produce high-molecular-weight fusion proteins. The preparations of recombinant antigen obtained from clones 1, 3, 4, 12, 33, 35, 101 , and 121 seem to be rather pure. Clone 29 showed a band in the highmolecular-weight area, but some lower-molecular-weight bands were also observed. The apparent molecular masses of the parasite-derived antigens containing the epitopes of clones 1, 3, 12, 33, 35 , and 29 were 90, 90, 50, 24, 25, and less than 20 kDa, respectively (Table 1) . No parasite-derived antigens were detected for clones 4 and 101, and clone 121 was not tested.
The purified recombinant antigens were tested for the presence of intact epitope by dot blot analysis with the sera previously used for identification as well as with additional LCL and DCL sera (Fig. 4) Compared with other screenings of similar genomic libraries that have been reported (17) , the present screening with human sera is quite efficient in terms of antigenic determinants detected per size of genome screened. With the most efficient serum (886), the score is about 1 positive clone per 3 x 102 kb screened (1 positive per 600 clones screened).
Almost all clones identified by the five test sera are different individual clones; only two pairs of clones were found to be identical. In the screening, no identical epitopes were identified by two or more of the sera tested, indicating that the antibodies present in each serum seem to be rather individual in terms of specificity. The dot blot analysis of partially purified antigens (Fig. 2) indicated that sera 886 and 1054 both react mainly with the antigens expressed by the clones originally isolated by using the same sera. However, some of the antigens that were not isolated with these sera in the screening test did react in the dot blot assay.
The analysis of the parasite-derived antigens from both an LCL and a DCL isolate by using the clone-specific antibodies showed that the antigenic patterns of the two isolates were essentially the same. Similar results have also been reported by others (12) . So, at least during in vitro cultivation, the expressed antigens of the LCL and DCL isolates are similar.
Many of the clone-specific antibodies recognize parasite antigens having the same molecular weight. For example, clone-specific antibodies 2 and 3 identify a 90-kDa antigen, antibodies 19 and 20 identify an 85-kDa antigen, and antibodies 15, 16, and 21 identify a 63-kDa antigen. Also, the two clone-specific antibodies 35 and 36 and the two antibodies 32 and 33 seem to recognize low-molecular-weight parasite antigens of similar size. These antigens could of course be different antigens having the same molecular weight; however, another explanation could be that the clone-specific antibodies recognize different epitopes on the same parasite antigen. Also, several clone-specific antibodies prepared in this study did not react in the Western blot analysis, and one reason might be that these antibodies are specific for amastigote antigens. However, inactivation of the antibodies during their preparation as well as inactivation of the epitopes during the SDS-PAGE could also be the reason for these results.
The results showing that clones isolated by DCL sera express epitopes present on high-molecular-weight parasite antigens whereas sera from LCL patients identified clones expressing epitopes on low-molecular-weight antigens are to some degree in contradiction to earlier reported results (12) . Because of the low number of sera used for screening in this study, no definite conclusion should be drawn; however, because of the large number of clone-specific antibodies tested, the observation is interesting. One should also bear in mind the different methods of detection in these cases (recombinant antigens in phage plaques versus promastigote antigens on Western blots). The results, however, could also reflect the rather large differences in antibody specificities observed between individual patients (12) .
The analysis of the purified antigens showed that antigen 29 (identified by serum 1054) seems to be recognized by all the test sera used, though some differences in antibody concentration exist. In addition, antigens 33 and 35 are recognized by most of the sera; this suggests that one or combinations of these antigens might serve as possible immunodiagnostic tools to assess the prevalence of L. aethiopica. However, further testing with a larger number of patient sera and sera from healthy noninfected individuals from areas of endemicity and nonendemicity will be necessary to evaluate the antigens for this purpose. It will also be important to test the antigens with sera from people having other infectious diseases in order to detect any crossreactivity of these antigens. A closer study of the recombinant antigens that were only partially purified in this study will also be important for this purpose. The reason it was only possible to purify 30% (9 of 31) of the recombinant antigens is not clear. This could be because of a lack of stability of the antigen, low solubility, or low affinity of the specific antigen for the anti-13-galactosidase column. However, to get reasonable amounts of antigenic material from these clones, other methods for purification or other vectorhost systems might be used.
We (5) . DNA hybridization studies or DNA sequencing of these clones should establish any relation of these clones with gp63. Further studies of the recombinant antigens from L. aethiopica described in this study will involve testing the antigens with a larger set of different sera. The recombinant antigens will also be tested for the presence of T-cell epitopes by possible stimulation of cells from LCL patients or healthy contacts.
